The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease
Open accessAbstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons of the substantia nigra pars compacta (SNpc). Although various treatments are successfully used to alleviate the symptoms of PD, none of them prevents or halts the neurodegenerative process of the disease. Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family of proteins, supports the survival and the differentiation of dopaminergic neurons. BDNF also prevents the death of dopaminergic neurons in vitro, which suggests that it may be of possible use in the development of neuroprotective therapies for PD. To determine whether BDNF is neuroprotective for SNpc dopaminergic neurons in the adult brain, we used a rat model of PD in which degeneration of 60-70% of these neurons was induced by an intrastriatal injection of 6-hydroxydopamine (6-OHDA). We report here that intrastriatal grafts of fibroblasts genetically engineered to produce BDNF partially prevent the loss of nerve terminals and completely prevent the loss of cell bodies of the nigrostriatal dopaminergic pathway that is induced by the intrastriatal injection of 6-OHDA. In contrast, the implantation of control fibroblasts that did not produce BDNF failed to protect nerve terminals and cell bodies against 6-OHDA-induced damage. Our observation that grafts of BDNF-producing fibroblasts protect against 6-OHDA-induced degeneration of SNpc dopaminergic neurons in the adult rat brain opens new perspectives for treatments aimed at the prevention of neurodegeneration in PD, using gene therapy and neurotrophic factors such as BDNF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the vast majority of studies with BDNF administration before induction of parkinsonism, the research results revealed at least partial prevention of neuronal cell loss [89,90,92,93,99,101].”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Estimation of nuclear population from microtome sections
Abercrombie, M. (1946) · The Anatomical Record · doi:10.1002/ar.1090940210 · Cited by 4,363
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,503
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Gerfen, C. R., Herkenham, M. A., & Thibault, J. (1987) · Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 804
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Altar, C. A., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 789
Sendtner, M., Holtmann, B., Kolbeck, R., Thoenen, H., & Barde, Y. (1992) · Nature · doi:10.1038/360757a0 · Cited by 706
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
Knüsel, B., Winslow, J. W., Rosenthal, A., Burton, L. E., Seid, D. P., Nikolics, K., & Hefti, F. F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.961 · Cited by 601
Research works printed but not linked: 1
- Jackson-Lewis V, Jakowec M, Burke RE, Przedbroski S (1995) Time course and morphology of dopaminergic neuronal death caused by neurotoxin I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurode- generation, in press.
Cited by
Sorted by citations
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
The impact of age, weight and gender on BDNF levels in human platelets and plasma
Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff‐Werner, P., & Virchow, J. C., Jr. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.002 · Cited by 849
Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease
Mattson, M. P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.005 · Cited by 640
Metadata
- Authors
- Levivier, M., Przedborski, S., Bencsics, C., & Kang, U.
- Affiliations
- Columbia University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 1995-12-01
- Volume
- 15
- Issue
- 12
- Pages
- 7810-7820
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6577965
- OpenAlex
- W1590012920
- Cited by
- 274
- References
- 25
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 11 · 2019: 5 · 2018: 9 · 2017: 3 · 2016: 9 · 2015: 11 · 2014: 11 · 2013: 8 · 2012: 9
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Irving A. Hansen Memorial Foundation
- National Institutes of Health (5r29ns032080-05, 5k08ns001724-03)
- Parkinsonfonden
- Fogarty International Center
- National Institute of Neurological Disorders and Stroke (1-K08-NS01724-01, R29 NS32080)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, brain-derived neurotrophic factor, dopaminergic neuron loss, substantia nigra pars compacta, 6-hydroxydopamine, gene therapy, neuroprotection, nigrostriatal pathway, neurotrophic factors
- MeSH terms
- Animals, Autoradiography, Corpus Striatum, Dopamine, Fibroblasts, Genetic Engineering, Male, Nerve Degeneration, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Rats, Inbred F344, Oxidopamine, Brain-Derived Neurotrophic Factor, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
